KDM6B过表达激活先天免疫信号并损害小鼠造血
研究构建Vav-KDM6B小鼠模型,发现KDM6B过表达单独仅致轻度造血表型,联合TLR配体LPS慢性刺激后出现白细胞减少、发育异常及造血干祖细胞再增殖功能受损等MDS/CMML特征。GSK-J4抑制KDM6B可改善小鼠无效造血及MDS患者原代造血干祖细胞再增殖功能。
要点
- KDM6B过表达联合LPS刺激可重现MDS/CMML样造血缺陷。
- KDM6B过表达激活S100a9等疾病相关及先天免疫基因。
- GSK-J4抑制KDM6B改善小鼠及MDS患者造血干祖细胞功能。
核心结论
- KDM6B过表达介导先天免疫信号激活,参与MDS和CMML发病,靶向KDM6B在这些髓系疾病中具有治疗潜力。
研究设计与样本
- 研究构建了在造血区室过表达KDM6B的Vav-KDM6B小鼠模型,并对其行TLR配体LPS慢性刺激。
- 转录组研究分析骨髓造血干祖细胞基因表达,并用小分子抑制剂GSK-J4进行药理学抑制实验。
- GSK-J4也应用于MDS患者原代骨髓造血干祖细胞以评估再增殖功能。
主要发现
- KDM6B过表达单独导致轻度造血表型,LPS慢性刺激后Vav-KDM6B小鼠出现显著造血缺陷,包括白细胞减少、发育异常和骨髓造血干祖细胞再增殖功能受损。
- 转录组显示KDM6B过表达单独可激活S100a9等疾病相关基因,联合先天免疫刺激后先天免疫及疾病相关基因过表达更显著。
- GSK-J4药理学抑制KDM6B改善了Vav-KDM6B小鼠的无效造血,并改善MDS患者原代骨髓造血干祖细胞的再增殖功能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KDM6B is an epigenetic regulator that mediates transcriptional activation during differentiation, including in bone marrow (BM) hematopoietic stem and progenitor cells (HSPCs). Overexpression of KDM6B has been reported in BM HSPCs of patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Whether the overexpression of KDM6B contributes to the pathogenesis of these diseases remains to be elucidated. To study this, we generated a Vav-KDM6B mouse model, which overexpresses KDM6B in the hematopoietic compartment. KDM6B overexpression alone led to mild hematopoietic phenotype, and chronic innate immune stimulation of Vav-KDM6B mice with the Toll-like receptor (TLR) ligand lipopolysaccharide (LPS) resulted in significant hematopoietic defects. These defects recapitulated features of MDS and CMML, including leukopenia, dysplasia, and compromised repopulating function of BM HSPCs. Transcriptome studies indicated that KDM6B overexpression alone could lead to activation of disease-relevant genes such as S100a9 in BM HSPCs, and when combined with innate immune stimulation, KDM6B overexpression resulted in more profound overexpression of innate immune and disease-relevant genes, indicating that KDM6B was involved in the activation of innate immune signaling in BM HSPCs. Finally, pharmacologic inhibition of KDM6B with the small molecule inhibitor GSK-J4 ameliorated the ineffective hematopoiesis observed in Vav-KDM6B mice. This effect was also observed when GSK-J4 was applied to the primary BM HSPCs of patients with MDS by improving their repopulating function. These results indicate that overexpression of KDM6B mediates activation of innate immune signals and has a role in MDS and CMML pathogenesis, and that KDM6B targeting has therapeutic potential in these myeloid disorders.
引用
- Wei Y, Zheng H, Bao N, et al. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice. Blood Adv. 2018. PMID: 30275007. doi:10.1182/bloodadvances.2018024166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。